About ATAI Life Sciences N.V. - Common Shares (ATAI)
Atai Life Sciences N.V. is a biopharmaceutical company focused on developing innovative therapies for mental health conditions. The company leverages the potential of psychedelics and other novel compounds to address various psychiatric disorders, aiming to create safer and more effective treatment options. Through a unique platform, Atai collaborates with several research biotechnology companies, fostering an environment that promotes scientific discovery, clinical innovation, and the advancement of transformative therapies for individuals suffering from mental health challenges. Read More
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to study MDMA with a focus on troops on active duty. The money will be provided by the U.S. Department of Defense (DOD).
PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expanding research and development efforts and a robust pipeline of novel medications, the neuropsychiatric disorders treatment landscape is evolving rapidly. Pharmaceutical companies are focusing on innovative drug therapies to meet the growing need for effective and affordable treatments. The market is primarily driven by the high incidence of mental illnesses, including depression and anxiety, and the rising awareness of these conditions. As a result, new treatment options are being developed, and drug-related activities such as clinical trials and drug approvals are intensifying. Recently an article on the 4th European Congress of Neurology and Neuropsychiatry website said that: “The global neuropsychiatric disorders and treatment market is on an upward trajectory, with a significant increase in demand for innovative solutions that cater to the growing burden of mental health conditions. In 2024, the market was valued at USD 130.5 billion, and by 2032, it is projected to reach USD 166.3 billion, growing at a compound annual growth rate (CAGR) of 10.20% from 2023 to 2032. This growth is fueled by continuous research, advancements in treatment, and heightened awareness of neuropsychiatric disorders.” Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Sage Therapeutics, Inc. (NASDAQ: SAGE), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), atai Life Sciences (NASDAQ: ATAI).
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg comparator group (p = 0.0038). For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p=0.0025 for change vs. 0.3 mg control). Notably, both the 8mg and 12mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to Week 8.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Atai Life Sciences N.V. (NASDAQ: ATAI) and Beckley Psytech Limited is fair to Atai shareholders.
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced a definitive agreement under which atai and Beckley plan to combine in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase 2b success criteria.
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June:
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression
